Previous 10 | Next 10 |
The following slide deck was published by Syneos Health, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Syneos Health, Inc. 2020 Q4 - Results - Earnings Call Presentation
Syneos Health (SYNH): Q4 Non-GAAP EPS of $1.11 beats by $0.01; GAAP EPS of $0.87 beats by $0.36.Revenue of $1.14B (-5.8% Y/Y) misses by $10M.Press Release For further details see: Syneos Health EPS beats by $0.01, misses on revenue
Highlights GAAP revenue of $1,140.0 million for the three months ended December 31, 2020, representing a sequential increase of 3.7% compared to the three months ended September 30, 2020. Net new business awards of $1,764.1 million and $5,863.1 million for the three and twel...
Syneos Health (NASDAQ:SYNH) is scheduled to announce Q4 earnings results on Thursday, February 18th, before market open.The consensus EPS Estimate is $1.10 (+6.8% Y/Y) and the consensus Revenue Estimate is $1.15B (-5.0% Y/Y).Over the last 2 years, SYNH has beaten EPS estimates 88% of the time...
PPD went public in February 2020, raising $1.6 billion in gross proceeds in a U.S. IPO. The firm provides contract research services to biopharmaceutical and research organizations worldwide. While Q3 saw strong growth from its COVID-19 study work, I believe the virus and its vari...
MORRISVILLE, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, is pulsing a series of 2021 Health Trends – Speed and Scale in the Great Disruption , offering new insights...
MORRISVILLE, N.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2020 financial results on Thursday, February 18, 2021, prior to its earnings call at...
OLINVYK - TRVN's main drug, an opioid painkiller - has a "value proposition" of >10x net savings for hospitals and a high level of initial inbound interest. Potential shortages of IV morphine/hydrocodone in part due to COVID-19 cases is leaving a gap that OLINVYK could potentially ...
Syneos Health ([[SYNH]] +0.3%) provides FY 2021 outlook in Form 8-K filing.Company expects revenue to be in the range of $5.125B-5.325B, growth rate 16.3-20.9%.Adjusted EBITDA $745B-785B, growth rate 18.3-24.6%.Adjusted EBITDA margin of 14.5-14.7%.Adjusted diluted EPS $4.09-4.38, growth rate ...
MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...